

Interim report Vigmed Holding AB (publ) January – September 2014

For further
information contact:

Chairman of the
board
Lennart Holm
+46 70 630 8562 or

CEO
Finn Ketler
+46 42 600 5311

- Net Sales for the first nine months was SEK 440 000 (compared to SEK 0 during 2013)
- Operating profit in the first nine months for the Group amounted to MSEK -22.4 (MSEK -16.4)
- Net income per share in the first nine months was SEK -0.59 (SEK -0.43).

During the first nine months of 2014, Vigmed Holding AB began production and sale of the product lines CLiP® Ported, CLiP® Neo and CLiP® Winged. Vigmed Holding AB's distribution partner, CODAN TRIPLUS AB, won its first hospital tender with Region Skåne in Sweden, for the patented product CLiP® Neo.

Vigmed Holding AB was granted Quality System Certificates for both EN ISO 13485:2012 and EN ISO 9001:2008. The certifications include development and manufacturing of solutions to prevent needlestick injuries.

Vigmed Holding AB established a legal entity in China, as a subsidiary to Vigmed China Ltd. in Hong Kong, for the purpose of initiating a registration process for products intended for the Chinese market.

After the reporting period on 9 October 2014, Vigmed Holding AB announced that the company will launch a unique arterial catheter on the market during 2015.

Furthermore, on 23 October 2014, the Board of Vigmed Holding AB decided – pursuant to the authority granted by the annual general meeting on 13 May 2014 – to issue not more than 6,261,904 shares through a preferential rights issue directed to existing shareholders thereby increasing the share capital not more than SEK 126,382.86. Assuming full subscription of the rights issue, the total issue proceeds amounts to approximately SEK 56.4 million before issue costs. The rights issue is fully guaranteed.

Teleconference on 24 October 2014 at 10:00 CET

Vigmed invites investors and media to a conference call (in English) on 24 October 2014 at 10:00 CET, where CEO Finn Ketler and Chairman of the Board Lennart Holm will present and comment on the interim report and rights issue and answer questions.